Antiphospholipid syndrome: a clinical review

Veronica Mezhov, Julian D Segan, Huyen Tran and Flavia M Cicuttini
Med J Aust 2019; 211 (4): . || doi: 10.5694/mja2.50262
Published online: 5 August 2019


  • Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous, microvascular) and/or pregnancy complications in the presence of persistent antiphospholipid antibodies (lupus anticoagulant, anti‐β2‐glycoprotein 1 and anticardiolipin).
  • It can be a primary disease or associated with another autoimmune disease (especially systemic lupus erythematosis).
  • Testing for antiphospholipid antibodies should be considered in patients < 50 years of age with unprovoked venous or arterial thromboembolism, thrombosis at unusual sites or pregnancy complications.
  • The mainstay of treatment is antithrombotic therapy and recommendations vary based on arterial, venous or pregnancy complications.
  • If associated with systemic lupus erythematosis, hydroxychloroquine is recommended both as primary and secondary prophylaxis.
  • Antithrombotic treatment is gold standard and effective.
  • Veronica Mezhov1
  • Julian D Segan1
  • Huyen Tran1,2
  • Flavia M Cicuttini1,2

  • 1 Alfred Health, Melbourne, VIC
  • 2 Monash University, Melbourne, VIC



We thank James McFadyen, Indi Rasaratnam, Juan Aw and Shom Bhattacharjee of Alfred Health for contributing to the content and review of this article.

Competing interests:

Huyen Tran has received grants from Bayer Health and Pfizer and speaker honoraria from Bayer Health and Boehringer Ingelheim.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.